Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
about
Neoadjuvant radiotherapeutic strategies in pancreatic cancerHistologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcomeNeoadjuvant therapy of pancreatic cancer: the emerging paradigm?Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomyThe expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.Outcomes from mesenteric-portal axis resection during pancreatectomyHistopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyExtended lymphadenectomy in patients with pancreatic cancer is debatable.When to puncture, when not to puncture: Pancreatic masses.Investigation and management of pancreatic tumours.Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.Augmented reality-guided artery-first pancreatico-duodenectomy.Is it time to stop checking frozen section neck margins during pancreaticoduodenectomy?Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
P2860
Q26766686-5AA2AA54-03FE-4ED9-861F-9ED1693EAD36Q35718282-DE92F2DF-11EC-457D-9441-E9030592188CQ35776229-83F6C7C7-6BD4-4139-BBCF-BE40F31B93E7Q35785646-567981FA-11B9-4189-AEF5-72C6795A5581Q35848380-60179BE0-599A-4C00-8699-826403E326B0Q36258194-A455FD5C-B836-481C-ACA6-15B520FCC6E4Q36268915-6205F11D-FA6A-4C02-910A-DA9BD66E7555Q36549820-73CE20C6-7A97-49DA-B2A5-DD458C9095ACQ36666622-56DF77DB-EB2B-497B-83E7-35EE720034C4Q37131693-E234FBC4-88B0-42B2-9716-3C5F6F6F7A36Q37322379-FA435A78-7F54-43A3-9FBC-99DFF4A48395Q37333036-81379CA5-F50A-44B9-AF65-7D203F2A6949Q37460276-8DA4E2FF-3B48-44BA-B4C7-FED6AA6E16D1Q37539690-0D989DDA-2E2F-46C8-AC87-0E4A0AE894A1Q38106907-505C54CD-7635-4253-80B3-E8297EA3EBEEQ38222441-8DCE390E-CC20-4644-A9C6-FA52D78F2847Q38609027-9F62978D-BFF9-47C2-924D-F9FD8022223AQ39342560-262CEEAE-532B-4C6D-B177-C780E6A62A3FQ40160341-249E67F3-86E6-48CD-A571-336B050ECEECQ40580320-19B17DA0-3CB7-49B4-8C77-46820576B90AQ44574799-76118640-6651-4972-8EF9-6098FE72D1D5Q45392240-D420B450-CE10-4A50-A2BF-15366F172B1FQ50118440-0FEE1E7A-BC75-4DAC-9A5D-F322CF247572
P2860
Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Post-therapy pathologic stage ...... th neoadjuvant chemoradiation.
@en
Post-therapy pathologic stage ...... th neoadjuvant chemoradiation.
@nl
type
label
Post-therapy pathologic stage ...... th neoadjuvant chemoradiation.
@en
Post-therapy pathologic stage ...... th neoadjuvant chemoradiation.
@nl
prefLabel
Post-therapy pathologic stage ...... th neoadjuvant chemoradiation.
@en
Post-therapy pathologic stage ...... th neoadjuvant chemoradiation.
@nl
P2093
P2860
P356
P1433
P1476
Post-therapy pathologic stage ...... th neoadjuvant chemoradiation.
@en
P2093
Asif Rashid
Douglas B Evans
Eddie K Abdalla
Gauri R Varadhachary
Henry F Gomez
Huamin Wang
James L Abbruzzese
Jason B Fleming
Jean-Nicolas Vauthey
P2860
P304
P356
10.1002/CNCR.26243
P407
P577
2011-07-06T00:00:00Z